BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26082033)

  • 1. Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma.
    Nie H; Li J; Yang XM; Cao QZ; Feng MX; Xue F; Wei L; Qin W; Gu J; Xia Q; Zhang ZG
    Hepatology; 2015 Oct; 62(4):1145-59. PubMed ID: 26082033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analyses identify miR-34c-3p/MAGI3 axis for the Warburg metabolism in hepatocellular carcinoma.
    Weng Q; Chen M; Yang W; Li J; Fan K; Xu M; Weng W; Lv X; Fang S; Zheng L; Song J; Zhao Z; Fan X; Ji J
    FASEB J; 2020 Apr; 34(4):5420-5434. PubMed ID: 32080912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect.
    Chen Z; Zuo X; Zhang Y; Han G; Zhang L; Wu J; Wang X
    Cell Death Dis; 2018 May; 9(5):549. PubMed ID: 29748591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened.
    Huang XH; Chen JS; Wang Q; Chen XL; Wen L; Chen LZ; Bi J; Zhang LJ; Su Q; Zeng WT
    J Pathol; 2011 Nov; 225(3):463-72. PubMed ID: 21671467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4).
    Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y
    Int J Clin Exp Pathol; 2015; 8(1):337-44. PubMed ID: 25755720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
    Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H
    Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The miR-125a/HK2 axis regulates cancer cell energy metabolism reprogramming in hepatocellular carcinoma.
    Jin F; Wang Y; Zhu Y; Li S; Liu Y; Chen C; Wang X; Zen K; Li L
    Sci Rep; 2017 Jun; 7(1):3089. PubMed ID: 28596599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-27a-3p suppresses tumor metastasis and VM by down-regulating VE-cadherin expression and inhibiting EMT: an essential role for Twist-1 in HCC.
    Zhao N; Sun H; Sun B; Zhu D; Zhao X; Wang Y; Gu Q; Dong X; Liu F; Zhang Y; Li X
    Sci Rep; 2016 Mar; 6():23091. PubMed ID: 26980408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients.
    Huang CY; Huang XP; Zhu JY; Chen ZG; Li XJ; Zhang XH; Huang S; He JB; Lian F; Zhao YN; Wu GB
    Oncol Rep; 2015 Jun; 33(6):2889-98. PubMed ID: 25962360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA.
    Hua S; Liu C; Liu L; Wu D
    Biochem Biophys Res Commun; 2018 Feb; 496(3):947-954. PubMed ID: 29360449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-34c-3p inhibits cell proliferation, migration and invasion of hepatocellular carcinoma by targeting MARCKS.
    Song J; Wang Q; Luo Y; Yuan P; Tang C; Hui Y; Wang Z
    Int J Clin Exp Pathol; 2015; 8(10):12728-37. PubMed ID: 26722462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
    Huang XP; Hou J; Shen XY; Huang CY; Zhang XH; Xie YA; Luo XL
    FEBS J; 2015 Feb; 282(3):579-94. PubMed ID: 25475121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galangin suppresses hepatocellular carcinoma cell proliferation by reversing the Warburg effect.
    Wang Y; Lin B; Li H; Lan L; Yu H; Wu S; Wu J; Zhang H
    Biomed Pharmacother; 2017 Nov; 95():1295-1300. PubMed ID: 28938520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer.
    Guo W; Qiu Z; Wang Z; Wang Q; Tan N; Chen T; Chen Z; Huang S; Gu J; Li J; Yao M; Zhao Y; He X
    Hepatology; 2015 Oct; 62(4):1132-44. PubMed ID: 26054020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
    Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
    Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase.
    Chang RM; Yang H; Fang F; Xu JF; Yang LY
    Hepatology; 2014 Oct; 60(4):1251-63. PubMed ID: 24825302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-592/WSB1/HIF-1α axis inhibits glycolytic metabolism to decrease hepatocellular carcinoma growth.
    Jia YY; Zhao JY; Li BL; Gao K; Song Y; Liu MY; Yang XJ; Xue Y; Wen AD; Shi L
    Oncotarget; 2016 Jun; 7(23):35257-69. PubMed ID: 27153552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma.
    Fang F; Chang RM; Yu L; Lei X; Xiao S; Yang H; Yang LY
    J Hepatol; 2015 Oct; 63(4):874-85. PubMed ID: 25998163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through interference with cell-cycle regulators.
    Wang P; Chen S; Fang H; Wu X; Chen D; Peng L; Gao Z; Xie C
    Oncotarget; 2016 Jan; 7(1):929-45. PubMed ID: 26498144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.